A volunteer attends to Alzheimer’s patients at a center for Alzheimer’s patients in Dax, southwestern France. US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer’s drug significantly slowed cognitive and functional decline, results hailed as “remarkable” by experts. In a placebo controlled trial of nearly 1,200 people with early forms of the disease, donanemab...
